ProBio CDMO

12/06/2022

Recently, Selecxine, a partner of GenScript ProBio, announced clearance of its phase I/II clinical trial application for innovative antibody drug program (SLC-3010) . This is the second clearance of Selecxine followed by their earlier approval from the US in July 2022.

Dr. Brian Hosung Min, CEO of GenScript ProBio said, "We congratulate Selecxine on MFDS clearance of its IND application, and we are honored to be part of this novel project. These IND clearances demonstrated our expertise in biopharmaceutical development and prove that our R&D capability and speed have reached the international level. We wish that this clinical study moves forward for the benefit of cancer patients as soon as possible."

https://www.genscriptprobio.com/genscript-probio-congratulates-selecxine-ind-clearance-from-mfds.html?utm_source=fb&utm_campaign=selecxine&utm_medium=social

12/05/2022

Program CD47, provided the service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp

Dr. Brian Hosung Min, CEO of GenScript ProBio said, “GenScript ProBio is committed to helping customers shorten the timeline for the development of biological drugs, significantly lowering R&D costs and shaping a healthier future. We are very pleased that this promising project will further be advanced by the joint venture between Pharma LLC and Iris Acquisition Corp. GenScript ProBio expects more patients will benefit from these two superior treatments.”

Learn more via https://www.genscriptprobio.com/program-cd47-provided-the-cmc-service-by-genscript-probio-to-innobationbio-will-further-be-advanced-by-the-joint-venture-between-liminatus-pharma-llc-and-iris-acquisition-corp.html?utm_source=fb&utm_campaign=cd47&utm_medium=social

12/02/2022

Join us for a 60 minutes webinar to know more about bi-specific strategies including cell line development, upstream process development, downstream process development, and analytical method development.

Tuesday | December 6th, 2022 | 10:00 AM ET

Ian Chan (CEO of Abpro) and Rubin Jiang (Director of antibody process development & MSAT group of GenScript ProBio) will be on hand to give you a look at -enabling CMC Strategies for Bispecific Antibodies.

Register here: https://lnkd.in/dFdgBB4d

12/01/2022

Join this webinar to learn more about the development of an exciting new and -enabling Strategies for and

Time: 2022.12.06 16:00-17:30 (AEDT)
Topic 1: Development of an exciting new radioimmunotherapy for cancer patients
Speaker 1: Dr Brad Walsh, CEO, GlyTherix Ltd

Topic 2: IND-enabling CMC Strategies for mAb and bsAb: Faster and Better
Speaker 2: Rubin Jiang, Director of Antibody Process Development & MSAT , GenScript ProBio
Details and Register link:
https://www.genscriptprobio.com/webinars/do-not-miss-genscript-probio-and-glytherix-live-webinar-on-06-december.html?utm_source=fb&utm_campaign=webinar&utm_medium=social

11/29/2022

Buchang Biopharmaceutical and REMD Biotherapeutics, partners of GenScript ProBio, recently received approval of BC008-1A from China for Phase 1 clinical trial. BC008-1A (NMPAIND number: CXSL2200315), a co-targeting the immune checkpoints PD-1 and TIGIT, for treatment of patients with advanced solid tumors. GenScript ProBio extends congratulations on this.

“We warmly congratulate our partners received IND approval of BC008-1A, an innovative bispecific antibody, from China NMPA. The approval of this program fully demonstrated that the SMABody® Platform has excellent developability and simple process manufacturing processes.” Dr. Brian Min, CEO of GenScript ProBio, said, “In the future, we will continue to support the innovative companies, such as REMD Bio and Buchang Biopharmaceutical, to bring new and improved treatment options to patients worldwide.”

Learn more via https://www.genscriptprobio.com/a-bispecific-antibody-molecule-jointly-developed-by-buchang-pharmaceutical-and-remd-biotherapeutics.html?utm_source=fb&utm_campaign=bc008&utm_medium=social

11/28/2022

GenScript ProBio, a leading Biologics to the bio-pharmaceutical market, and , developers of a novel silencing variant, announced a licensing deal for mAbsolve's Fc silencing technology. The agreement provides GenScript ProBio with access to the new STR Fc silencing platform. The agreement provides GenScript ProBio's clients with easy license-free access to the new STR Fc silencing platform for antibody research and development.

“GenScript ProBio has a deep accumulation in the discovery and development of antibody drugs, and we are committed to accelerating drug research and development and improving quality of products,” said Dr. Brian Hosung Min, CEO of GenScript ProBio. “We are excited to partner with the mAbsolve team, who have a wealth of knowledge and experience in developing therapeutic antibodies, their novel Fc silencing technology will enhance drug efficacy for our clients.”

learn more via

GenScript ProBio, a leading Biologics CDMO to the bio-pharmaceutical market, and mAbsolve, developers of a novel Fc silencing variant, announced a licensing deal for mAbsolve’s Fc silencing technology. The agreement provides GenScript ProBio with access to the new STR Fc silencing platform. The ag...

11/25/2022

Are you puzzled about the analytical control strategy for different plasmid DNA product applications? If so, don't hesitate, come and join us for the upcoming webinar!

Wednesday | November 30th, 2022 | 3:00PM GMT

In this , we will discuss:
• Understand the diverse applications of products in the market
• Explore the latest guidelines from and discussing both commercial applications and clinical trial materials
• Learn the whole picture of analytical control for plasmid DNA products and discover the challenges
• Seek the current best practice from some case studies.

Register now to reserve your seat: https://lnkd.in/eWgevDht

11/24/2022

(RIT) is an emerging approach for the diagnosis, therapy, and monitoring of solid tumors. It is a great honor to invite Dr Brad Walsh, CEO of , to share a topic on the development of exciting new radioimmunotherapy for cancer patients.

Next will be the director from process development department of GenScript ProBio, sharing IND-enable CMC Strategies for monoclonal antibodies and bsAbs: Faster and Better.

Details

Time: 2022.12.06 16:00-17:30 (AEDT)
Topic 1: Development of an exciting new radioimmunotherapy for cancer patients
Speaker 1: Dr Brad Walsh, CEO, Ltd

Topic 2: IND-enabling Strategies for and : Faster and Better
Speaker 2: Rubin Jiang, Director of Antibody Process Development & MSAT , GenScript ProBio

Details and Register link:https://www.genscriptprobio.com/webinars/do-not-miss-genscript-probio-and-glytherix-live-webinar-on-06-december.html?utm_source=fb&utm_campaign=webinar&utm_medium=social

10/26/2022

We are glad to share with you our knowledge of development and manufacturing strategy for base vaccine-drug candidates.

In this , you will learn:
• DNA based /drug MKT trend
• development and manufacturing strategy
• Plasmid platform in GenScript ProBio: 20 approvals in CN, AP, EU and US

Please register at the link below and join us to discuss further with our professional director.

Registration Link: https://lnkd.in/eFDWT3_Z

10/19/2022

Welcome to visit our booth (66B) in Bio Europe conference. We are glad to share our services about antibody & protein biologics (experienced with 17 clearances), cell & gene therapy (experienced with 20 IND approvals in AP, EU, CN, US) to you.

Know about our Fast -mAb: as fast as 6 months from DNA to TOX delivery

Know about our Custom Plasmid Manufacturing: one-stop solution, from cell banking to PD, AD, GMP MFG and stability study.

Conference: Bio Europe
Time: 2022.10.24 9:00 – 10.26 12:30
Booth No: 66B
Location: Leipzig, Germany
Link: https://lnkd.in/dnuNZ2D

10/18/2022

GenScript ProBio Signs to Form Strategic Partnership with To Development and Production of New gene therapies.

Brian H. Min, CEO of GenScript ProBio said, "We are very happy to cooperate with GeneCraft in strategic partnership, and we are looking forward to accelerating the development of GeneCraft’s gene therapy pipelines as a global partner through our accumulated technology.”

Learn more: https://www.genscriptprobio.com/genscript-probio-signs-mou-to-form-strategic-partnership-with-genecraft-to-development-and-production-of-new-aav-gene-therapies.html?utm_source=fb&utm_campaign=genecraft&utm_medium=social

09/14/2022

The registration function of ProBio website is available now! if you have a ProBio login, you will receive
 Latest industry news and message
 ProBio service or promotion
 Conference or Webinar information
 Resources: handbook, flyer, white paper, case study etc.
 Other useful information
Join ProBio and start an exciting journey https://www.genscriptprobio.com/customer/signup?utm_source=fb&utm_campaign=isct&utm_medium=social